<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Raz, Itamar</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">DiaPep277® Shows Promise as a Therapeutic Strategy for Type 1 Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Administration of DiaPep277® is safe and represents a promising therapeutic strategy in patients with recent-onset type 1 diabetes (T1DM). Results of two large Phase 3 trials will determine if this therapy might change the current approach to treating newly diagnosed T1DM patients [Tuccinardi D et al. Expert Opin Biol Ther 2011].</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>